> 首页 > 产品 > 一抗 > 其他 > Anti-CD3 & CD20 Reference Antibody (Epcoritamab)

Anti-CD3 & CD20 Reference Antibody (Epcoritamab)

Anti-CD3 & CD20 Reference Antibody (Epcoritamab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.
The purity of Anti-CD3 & CD20 Reference Antibody (Epcoritamab) is more than 99.00%, determined by SEC-HPLC.
Epcoritamab bound to CD3e protein, and then rebounded to secondary antibodies (Anti-human-κ+λ-HRP) , and read OD450. As shown in fig, Epcoritamab bound to hu-CD3e-Fc, and the EC50 was 0.024 nM.
Epcoritamab bound to CD20 protein, and then rebounded to secondary antibodies (Anti-human-IgG-Fc-HRP) , and read OD450. As shown in fig, Epcoritamab bound to hu-CD20-VLP, and the EC50 was 0.095 nM.
Epcoritamab bound to huCD3e-jurkat cells, and then rebounded to fluorescent secondary antibodies (Anti-human IgG, Fcγ PE) , and test by flow cytometry. As shown in fig, Epcoritamab bound to huCD3e-jurkat cells, and the EC50 was 18.920 nM.
Epcoritamab bound to Raji cells, and then rebounded to fluorescent secondary antibodies (Anti-human IgG, Fcγ PE) , and test by flow cytometry. As shown in fig, Epcoritamab bound to Raji cells, and the EC50 was 8.393 nM.
Co-incubation of Epcoritamab with Jurkat cells, then with the addition of Raji cells for 6 hours. Bright-Lite was used to detect the fluorescent signal.As shown in fig, Epcoritamab was able to activate the NF-AT signaling pathway, and the EC50 was 0.009 nM.

产品详情
实验流程

Product Information
Application Applications Legend: E=ELISA WB=Western Blotting IHC=Immunohistochemistry IHC-P=Immunohistochemistry (Paraffin) IP=Immunoprecipitation IF=Immunofluorescence IC=Immunochemistry ICC=Immunocytochemistry FC=Flow Cytometry DB=Dot Blot	Functional assay, Kinetics (SPR), Kinetics (BLI), FACS, E, FTA
Primary Accession	P07766 & P11836
Reactivity	Human
Clonality	Bispecific
Isotype	IgG-like

Additional Information
Target/Specificity	CD20,CD3
Expression system	CHO

For Research Use Only. Not For Use In Diagnostic Procedures.

Patent Notice: The variable region sequence of this antibody is derived from a published third-party patent. This product is manufactured independently as a Research Use Only (RUO) reagent and is not licensed, sponsored, or endorsed by the patent holder. It is intended solely for research purposes. Customers considering any commercial, diagnostic, or therapeutic use should independently evaluate freedom-to-operate with respect to relevant third-party patents.